Radezolid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Radezolid
- DrugBank Accession Number
- DB12339
- Background
Radezolid has been used in trials studying the treatment of Abscess, Bacterial Skin Diseases, Streptococcal Infections, Infectious Skin Diseases, and Staphylococcal Skin Infections, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 438.463
Monoisotopic: 438.181566788 - Chemical Formula
- C22H23FN6O3
- Synonyms
- Radezolid
- External IDs
- AND RX-01_667
- RX-013
- RX-103
- RX-1741
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism URibosome-binding protein 1 inhibitorHumans U50S ribosomal protein L1 binderStaphylococcus aureus (strain NCTC 8325) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Radezolid is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Radezolid is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Radezolid is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Radezolid. Benzocaine The risk or severity of methemoglobinemia can be increased when Radezolid is combined with Benzocaine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Radezolid hydrochloride 37CW568NXL 869884-77-5 UQKABVKLBIJYBI-FYZYNONXSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Biphenyls and derivatives
- Direct Parent
- Biphenyls and derivatives
- Alternative Parents
- Phenylmethylamines / Benzylamines / Aralkylamines / Fluorobenzenes / Aryl fluorides / Oxazolidinones / Triazoles / Carbamate esters / Heteroaromatic compounds / Dialkylamines show 8 more
- Substituents
- 1,2,3-triazole / Amine / Aralkylamine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Azole / Benzylamine / Biphenyl show 24 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 53PC6LO35W
- CAS number
- 869884-78-6
- InChI Key
- BTTNOGHPGJANSW-IBGZPJMESA-N
- InChI
- InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
- IUPAC Name
- N-{[(5S)-3-[2-fluoro-4'-({[(1H-1,2,3-triazol-5-yl)methyl]amino}methyl)-[1,1'-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
- SMILES
- CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C(F)=C1)C1=CC=C(CNCC2=CN=NN2)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11224409
- PubChem Substance
- 347828598
- ChemSpider
- 9399462
- ChEMBL
- CHEMBL455461
- ZINC
- ZINC000040379938
- PDBe Ligand
- RD8
- Wikipedia
- Radezolid
- PDB Entries
- 6wqq / 7s1i / 7s1j / 7s1k
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Abscesses / Bacterial skin infections / Skin Diseases, Infectious / Staphylococcal Skin Infections / Streptococcal Infections 1 2 Completed Treatment Community Acquired Pneumonia (CAP) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.043 mg/mL ALOGPS logP 1.23 ALOGPS logP 1.29 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 8.56 Chemaxon pKa (Strongest Basic) 7.46 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 112.24 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 115.89 m3·mol-1 Chemaxon Polarizability 45.19 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0002900000-f2b9228e465c69af2b67 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-2109000000-e51d7095806d1e38cfb6 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000b-1009400000-cdffa4188f3a68790a9d Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00bd-1009000000-5d25db3988037029034f Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0nni-4339200000-513b0fac76098b23fa38 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-7009300000-be0e88182ab279f00b43 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 192.201 predictedDeepCCS 1.0 (2019) [M+H]+ 194.59656 predictedDeepCCS 1.0 (2019) [M+Na]+ 200.5091 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsRibosome-binding protein 1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Receptor activity
- Specific Function
- Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane.
- Gene Name
- RRBP1
- Uniprot ID
- Q9P2E9
- Uniprot Name
- Ribosome-binding protein 1
- Molecular Weight
- 152471.765 Da
References
- Shriwas O, Arya R, Mohanty S, Mohapatra P, Kumar S, Rath R, Kaushik SR, Pahwa F, Murmu KC, Majumdar SKD, Muduly DK, Dixit A, Prasad P, Nanda RK, Dash R: RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway. Br J Cancer. 2021 Jun;124(12):2004-2016. doi: 10.1038/s41416-021-01336-7. Epub 2021 Mar 24. [Article]
2. Details50S ribosomal protein L1
- Kind
- Protein
- Organism
- Staphylococcus aureus (strain NCTC 8325)
- Pharmacological action
- Unknown
- Actions
- Binder
- Curator comments
- Radezolid binds to the 50s ribosomal subunit of different bacterial species, including S. aureus.
- General Function
- Binds directly to 23S rRNA. The L1 stalk is quite mobile in the ribosome, and is involved in E site tRNA release.
- Specific Function
- Rna binding
- Gene Name
- rplA
- Uniprot ID
- Q2G0P0
- Uniprot Name
- 50S ribosomal protein L1
- Molecular Weight
- 24708.165 Da
References
- Skripkin E, McConnell TS, DeVito J, Lawrence L, Ippolito JA, Duffy EM, Sutcliffe J, Franceschi F: R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. Antimicrob Agents Chemother. 2008 Oct;52(10):3550-7. doi: 10.1128/AAC.01193-07. Epub 2008 Jul 28. [Article]
- Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F: Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59. doi: 10.1128/AAC.01724-09. Epub 2010 Apr 12. [Article]
Drug created at October 20, 2016 22:00 / Updated at March 14, 2023 09:13